Skip to content
Parakho

Sai Parenterals Ltd

NSE SAIPARENTBSE 544742saiparenterals.com

Q1 FY27, unaudited

Revenue
₹52.78 Cr
Profit after tax
₹8.88 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations52.78—162.25
Other income3.41—2.74
Total income56.19—164.99
Employee benefit expense3.34—14.30
Finance costs3.57—8.77
Depreciation & amortisation1.36—5.78
Total expenses44.36—146.22
Profit before tax11.83—18.77
Tax expense2.96—1.99
Profit after tax8.88—16.78
Total comprehensive income8.88—16.86
Earnings per share
Earnings per share, basic₹2.01₹5.13
Earnings per share, diluted₹2.01₹5.13

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q1 FY27

Sai Parenterals reported Q1 FY'27 consolidated revenue of Rs. 182 crores with EBITDA of Rs. 27 crores at a 14.9% margin, and management attributed a sequential margin gain to price revision recovery lags unwinding, offset partly by air freight costs incurred in Australia due to disruption in shipments from the Indian contract manufacturing network. The Board approved redeploying Rs. 101.85 crores of IPO proceeds, originally earmarked for capacity upgradation and an R&D center, toward 60% stakes in Saicriti Pharma and Prathyak Laboratories, citing a Telangana government policy restricting upgradations within the outer ring road. Management reiterated full-year guidance of Rs. 750 crores revenue at approximately 17% EBITDA margin for FY'27, describing the year as weighted toward the second half.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 55 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.